Document is current
Any future updates will be listed below
-
Authors
Moore, Michael R.
Friesner, Isabel D.
Rizk, Emanuelle M.
Fullerton, Benjamin T.
Mondal, Manas
Trager, Megan H.
Mendelson, Karen
Chikeka, Ijeuru
Kurc, Tahsin
Gupta, Rajarsi
Rohr, Bethany R.
Robinson, Eric J.
Acs, Balazs
Chang, Rui
Kluger, Harriet
Taback, Bret
Geskin, Larisa J.
Horst, Basil
Gardner, Kevin
Niedt, George
Celebi, Julide T.
Gartrell-Corrado, Robyn D.
Messina, Jane
Ferringer, Tammie
Rimm, David L.
Saltz, Joel
Wang, Jing
Vanguri, Rami
Saenger, Yvonne M.
-
Funding
Funding for this research was provided by:
Yale SPORE in Skin Cancer,United States (P50 CA121974)
Navigate BioPharma
National Institutes of Health (UH2CA218149)
Irving Institute for Clinical and Translational Research
- License Information
-
More Information
Article History
Received: 20 July 2020
Accepted: 13 January 2021
First Online: 2 February 2021
Competing interests
: Dr. Saenger has received research funding from Amgen and Regeneron. In addition, she is co-founder of a small biomarkers start-up company, Wasaba. All other authors declare no competing interests.
